List of Fenoglide drug patents

Fenoglide is owned by Salix.

Fenoglide contains Fenofibrate.

Fenoglide has a total of 4 drug patents out of which 0 drug patents have expired.

Fenoglide was authorised for market use on 10 August, 2007.

Fenoglide is available in tablet;oral dosage forms.

Fenoglide can be used as use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, for reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia.

The generics of Fenoglide are possible to be released after 09 December, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481078 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(1 year, 7 months from now)

US8124125 SALIX Solid dosage form comprising a fibrate
Oct, 2024

(1 year, 7 months from now)

US9173847 SALIX Tablet comprising a fibrate
Oct, 2024

(1 year, 7 months from now)

US7658944 SALIX Solid dosage form comprising a fibrate
Dec, 2024

(1 year, 10 months from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 10 August, 2007

Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia

Dosage: TABLET;ORAL

How can I launch a generic of FENOGLIDE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in